Cite
HARVARD Citation
Petrylak, D. et al. (n.d.). 343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921). Journal for immunotherapy of cancer. p. A368. [Online].